View Item 

Show simple item record

Pharmacokinetics of Intravenously Administered Levofloxacin in Men and Women
dc.contributor.authorOverholser, Brian R.en_US
dc.contributor.authorKays, Michael B.en_US
dc.contributor.authorLagvankar, Seemaen_US
dc.contributor.authorGoldman, Mitchellen_US
dc.contributor.authorMueller, Bruce A.en_US
dc.contributor.authorSowinski, Kevin M.en_US
dc.date.accessioned2012-03-16T16:00:34Z
dc.date.available2012-03-16T16:00:34Z
dc.date.issued2005-10en_US
dc.identifier.citationOverholser, Brian R.; Kays, Michael B.; Lagvankar, Seema; Goldman, Mitchell; Mueller, Bruce A.; Sowinski, Kevin M. (2005). "Pharmacokinetics of Intravenously Administered Levofloxacin in Men and Women." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 25(10). <http://hdl.handle.net/2027.42/90350>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90350
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherSex‐Based Differencesen_US
dc.subject.otherPharmacokineticsen_US
dc.subject.otherLevofloxacinen_US
dc.titlePharmacokinetics of Intravenously Administered Levofloxacin in Men and Womenen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Clinical Sciences, University of Michigan College of Pharmacy, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indianaen_US
dc.contributor.affiliationotherDepartment of Pharmacy Practice, Purdue University School of Pharmacy and Pharmaceutical Sciences, Indianapolis and West Lafayette, Indianaen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90350/1/phco.2005.25.10.1310.pdf
dc.identifier.doi10.1592/phco.2005.25.10.1310en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceSchwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet 2003; 42: 107 – 21.en_US
dc.identifier.citedreferenceSörgel F, Naber KG, Mahr G, et al. Gender related distribution of quinolones. Eur J Clin Microbiol Infect Dis 1990: 20 – 1.en_US
dc.identifier.citedreferenceBertino JS Jr, Nafziger AN Pharmacokinetics of oral fleroxacin in male and premenopausal female volunteers. Antimicrob Agents Chemother 1996; 40: 789 – 91.en_US
dc.identifier.citedreferenceShah A, Lettieri J, Nix D, Wilton J, Heller AH. Pharmacokinetics of high‐dose intravenous ciprofloxacin in young and elderly and in male and female subjects. Antimicrob Agents Chemother 1995; 39: 1003 – 6.en_US
dc.identifier.citedreferenceEfthymiopoulos C, Bramer SL, Maroli A. Effect of age and gender on the pharmacokinetics of grepafloxacin. Clin Pharmacokinet 1997; 33 ( suppl 1 ): 9 – 17.en_US
dc.identifier.citedreferenceOverholser BR, Kays MB, Forrest A, Sowinski KM. Sex‐related differences in the pharmacokinetics of oral ciprofloxacin. J Clin Pharmacol 2004; 44: 1012 – 22.en_US
dc.identifier.citedreferenceSowinski KM, Abel SR, Clark WR, Mueller BA. Effect of gender on the pharmacokinetics of ofloxacin. Pharmacotherapy 1999; 19: 442 – 6.en_US
dc.identifier.citedreferenceHoffler D, Dalhoff A, Gau W, Beermann D, Michl A. Dose‐ and sex‐independent disposition of ciprofloxacin. Eur J Clin Microbiol 1984; 3: 363 – 6.en_US
dc.identifier.citedreferenceGallicano K, Sahai J. Lack of gender effect on ciprofloxacin pharmacokinetics in humans. Br J Clin Pharmacol 1996; 42: 632 – 4.en_US
dc.identifier.citedreferenceExpert Panel on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998; 158: 1855 – 67.en_US
dc.identifier.citedreferenceDevine B. Case study number 25: gentamicin therapy. Drug Intell Clin Pharm 1974; 8: 650 – 5.en_US
dc.identifier.citedreferenceHaycock GB, Schwartz GJ, Wisotsky DH. Geometric method for measuring body surface area: a height‐weight formula validated in infants, children, and adults. J Pediatr 1978; 93: 62 – 6.en_US
dc.identifier.citedreferenceGreen B, Duffull SB. Development of a dosing strategy for enoxaparin in obese patients. Br J Clin Pharmacol 2003; 56: 96 – 103.en_US
dc.identifier.citedreferenceLiang H, Kays MB, Sowinski KM. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high‐performance liquid chromatography: application to levofloxacin determination in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 772: 53 – 63.en_US
dc.identifier.citedreferenceD'Argenio D, Schumitzky A. ADAPT II user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles: University of Southern California, Biomedical Simulations Resource, 1992.en_US
dc.identifier.citedreferenceAkaike H. An information criterion (AIC). Math Sci 1976; 153: 5 – 9.en_US
dc.identifier.citedreferenceGibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker, 1982.en_US
dc.identifier.citedreferenceYamaguchi H, Yano I, Hashimoto Y, Inui KI. Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco‐2. J Pharmacol Exp Ther 2000; 295: 360 – 6.en_US
dc.identifier.citedreferenceMorris ME, Lee HJ, Predko LM. Gender differences in the membrane transport of endogenous and exogenous compounds. Pharmacol Rev 2003; 55: 229 – 40.en_US
dc.identifier.citedreferenceChow AT, Fowler C, Williams RR, Morgan N, Kaminski S, Natarajan J. Safety and pharmacokinetics of multiple 750‐milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother 2001; 45: 2122 – 5.en_US
dc.identifier.citedreferenceHayakawa H, Takagi K, Takano YF, Kawamura Y, Tsuji A. Determinant of the distribution volume at steady state for novel quinolone pazufloxacin in rats. J Pharm Pharmacol 2002; 54: 1229 – 36.en_US
dc.identifier.citedreferenceCakmakci M, Gossweiler L, Schilling J, Schlumpf R, Geroulanos S. Penetration of fleroxacin into human lung, muscle, and fat tissue. Drugs Exp Clin Res 1992; 18: 299 – 302.en_US
dc.identifier.citedreferenceMertes PM, Voiriot P, Dopff C, et al. Penetration of ciprofloxacin into heart valves, myocardium, mediastinal fat, and sternal bone marrow in humans. Antimicrob Agents Chemother 1990; 34: 398 – 401.en_US
dc.identifier.citedreferenceFong IW, Ledbetter WH, Vandenbroucke AC, Simbul M, Rahm V. Ciprofloxacin concentrations in bone and muscle after oral dosing. Antimicrob Agents Chemother 1986; 29: 405 – 8.en_US
dc.identifier.citedreferenceSawada M, Saishu Y, Hayashi SL. Post‐marketing surveillance of levofloxacin in Japan [abstr]. Can J Infect Dis 1995; 6 ( suppl C ): 385C.en_US
dc.identifier.citedreferenceGeddes AM. Safety of fleroxacin in clinical trials. Am J Med 1993; 94: S201 – 3.en_US
dc.identifier.citedreferenceChien SC, Chow AT, Natarajan J, et al. Absence of age and gender effects on the pharmacokinetics of a single 500‐milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 1997; 41: 1562 – 5.en_US
dc.identifier.citedreferenceLipsky BA, Baker CA. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 1999; 28: 352 – 64.en_US
dc.identifier.citedreferenceShepard CW, Soriano‐Gabarro M, Zell ER, et al. Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence. Emerg Infect Dis 2002; 8: 1124 – 32.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.2005.25.10.1310.pdf
Size:
157.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.